The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
Future Oncol
; 13(23): 2045-2051, 2017 Oct.
Article
en En
| MEDLINE
| ID: mdl-29019414
ABSTRACT
AIM:
We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. MATERIALS &METHODS:
We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients).RESULTS:
THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis.DISCUSSION:
We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples.CONCLUSION:
Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Biomarcadores de Tumor
/
Telomerasa
/
Metilación de ADN
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Portugal